Trial Profile
Persistence of the effects of Cerebrolysin (FPF 1070) on cognition and qEEG slowing in vascular dementia patients: Results of a 3-month extension study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2011
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Vascular dementia
- Focus Therapeutic Use
- 14 Mar 2011 New trial record